Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)

被引：27
|
作者：
Cortes, Jorge E.
Tallman, Martin S.
Schiller, Gary
Trone, Denise
Gammon, Guy
Goldberg, Stuart
Perl, Alexander E.
Marie, Jean Pierre
Martinelli, Giovanni
Levis, Mark
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.494.494
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
494
引用
收藏
页数：2
相关论文
共 50 条
  • [1] QUIZARTINIB (AC220) IN PATIENTS WITH FLT3-ITD(+) RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: FINAL RESULTS OF A RANDOMIZED PHASE 2 STUDY
    Russell, N.
    Tallman, M. S.
    Goldberg, S.
    Perl, A. E.
    Marie, J. P.
    Martinelli, G.
    Larson, R. A.
    Schiller, G.
    Trone, D.
    Gammon, G.
    Levis, M.
    Cortes, J. E.
    HAEMATOLOGICA, 2014, 99 : 36 - 36
  • [2] A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results
    Cortes, Jorge E.
    Perl, Alexander E.
    Smith, Catherine C.
    Kovacsovics, Tibor
    Dombret, Herve
    Dohner, Hartmut
    Steffen, Bjorn
    Pigneux, Arnaud
    Rousselot, Philippe
    Krauter, Juergen
    Martinelli, Giovanni
    Estey, Elihu H.
    Burnett, Alan K.
    Ho, Anthony D.
    Ifrah, Norbert
    de Witt, Theo
    Corringham, Robert
    James, Joyce
    Lilienfeld, David
    Leo, Eugen
    Gammon, Guy
    Levis, Mark J.
    BLOOD, 2011, 118 (21) : 1105 - 1105
  • [3] Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia.
    Schiller, Gary J.
    Tallman, Martin S.
    Goldberg, Stuart L.
    Perl, Alexander E.
    Marie, Jean-Pierre
    Martinelli, Giovanni
    Larson, Richard A.
    Russell, Nigel
    Trone, Denise
    Gammon, Guy
    Levis, Mark J.
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Efficacy and safety of quizartinib (AC220) in patients age ≥ 70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML).
    Perl, Alexander E.
    Dohner, Hartmut
    Rousselot, Philippe H.
    Marie, Jean-Pierre
    Martinelli, Giovanni
    Shah, Neil P.
    Levis, Mark J.
    Gammon, Guy
    Trone, Denise
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study
    Takeshi Takahashi
    Kensuke Usuki
    Kosei Matsue
    Hitoshi Ohno
    Toru Sakura
    Ryota Imanaka
    Masato Murakami
    Shoichi Ohwada
    Taiga Takagi
    Sakura Sakajiri
    International Journal of Hematology, 2019, 110 : 665 - 674
  • [6] Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study
    Takahashi, Takeshi
    Usuki, Kensuke
    Matsue, Kosei
    Ohno, Hitoshi
    Sakura, Toru
    Imanaka, Ryota
    Murakami, Masato
    Ohwada, Shoichi
    Takagi, Taiga
    Sakajiri, Sakura
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (06) : 665 - 674
  • [7] Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia
    Cortes, Jorge E.
    Perl, Alexander E.
    Dombret, Herve
    Kayser, Sabine
    Steffen, Bjoern
    Rousselot, Philippe
    Martinelli, Giovanni
    Estey, Elihu H.
    Burnett, Alan K.
    Gammon, Guy
    Trone, Denise
    Leo, Eugen
    Levis, Mark J.
    BLOOD, 2012, 120 (21)
  • [8] TREATMENT WITH QUIZARTINIB (AC220) ENABLES A HIGH RATE OF PATIENTS WITH RELAPSED OR REFRACTORY FLT3-ITD(+) ACUTE MYELOID LEUKEMIA TO BE BRIDGED TO HSCT
    Martinelli, G.
    Levis, M. J.
    Perl, A. E.
    Dombret, H.
    Steffen, B.
    Rousselot, P.
    Estey, E. H.
    Shah, N. P.
    Gammon, G.
    Trone, D.
    Cortes, J. E.
    HAEMATOLOGICA, 2014, 99 : 35 - 35
  • [9] EFFICACY AND SAFETY OF QUIZARTINIB (AC220) IN PATIENTS AGE ≥60 YEARS WITH FLT3-ITD-POSITIVE RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
    Doehner, H.
    Perl, A.
    Rousselot, P.
    Marie, J.
    Martinelli, G.
    Gammon, G.
    Trone, D.
    Cortes, J.
    Levis, M.
    HAEMATOLOGICA, 2013, 98 : 233 - 233
  • [10] Results Of a Phase 1 Study Of Quizartinib (AC220, ASP2689) In Combination With Induction and Consolidation Chemotherapy In Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
    Altman, Jessica K.
    Foran, James M.
    Pratz, Keith W.
    Trone, Denise
    Gammon, Guy
    Cortes, Jorge E.
    Tallman, Martin S.
    BLOOD, 2013, 122 (21)
12345